Cognitive dysfunction in bipolar disorder: Future place of pharmacotherapy

CNS Drugs

Volumn 21, Issue 12, 2007, Pages 971-981

  Burdick, Katherine E ^a,b,c   Braga, Raphael J ^a   Goldberg, Joseph F ^d   Malhotra, Anil K ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorders; Cholinesterase inhibitors, therapeutic use; Cognitive function; Dopamine receptor agonists, therapeutic use; Dopamine receptor antagonists, therapeutic use; Glutamate release antagonists, therapeutic use

Indexed keywords

BROMOCRIPTINE; CARBAMAZEPINE; CATECHOL METHYLTRANSFERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; GALANTAMINE; HALOPERIDOL; LAMOTRIGINE; MEMANTINE; MIFEPRISTONE; OLANZAPINE; PERGOLIDE; PERPHENAZINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ALZHEIMER DISEASE; ATTENTION; BIPOLAR DEPRESSION; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEARNING; LONG TERM POTENTIATION; MANIA; MEMORY; MOUSE STRAIN; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOM;

BIPOLAR DISORDER; COGNITION DISORDERS; HUMANS; NOOTROPIC AGENTS;

EID: 36248982558     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721120-00002     Document Type: Review

References (83)

1. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990
2. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996; 274 (5288): 740-3
3. Basso MR, Lowery N, Neel J, et al. Neuropsychological impairment among manic, depressed, and mixed-episode inpatients with bipolar disorder. Neuropsychology 2002; 16 (1): 84-91
4. Martinez-Aran A, Vieta E, Colom F, et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 2000; 69 (1): 2-18
5. Martinez-Aran A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004; 161 (2): 262-70
6. Harmer CJ, Clark L, Grayson L, et al. Sustained attention deficit in bipolar disorder is not a working memory impairment in disguise. Neuropsychologia 2002; 40 (9): 1586-90
7. Liu SK, Chiu CH, Chang CJ, et al. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. Am J Psychiatry 2002; 159 (6): 975-82
8. Ferrier IN, Stanton BR, Kelly TP, et al. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 1999; 175: 246-51
9. Rubinsztein JS, Michael A, Paykel ES, et al. Cognitive impairment in remission in bipolar affective disorder. Psychol Med 2000; 30 (5): 1025-36
10. van Gorp WG, Altshuler L, Theberge DC, et al. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence: a preliminary study. Arch Gen Psychiatry 1998; 55 (1): 41-6
11. Zubieta JK, Huguelet P, O'Neil RL, et al. Cognitive function in euthymic bipolar I disorder. Psychiatry Res 2001; 102 (1): 9-20
12. Martinez-Aran A, Vieta E, Colom F, et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004; 6 (3): 224-32
13. Najt P, Glahn D, Bearden CE, et al. Attention deficits in bipolar disorder: a comparison based on the Continuous Performance Test. Neurosci Lett 2005; 379 (2): 122-6
14. Rung JP, Carlsson A, Markinhuhta KR, et al. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 (5): 833-9
15. Sereno AB, Holzman PS. Spatial selective attention in schizophrenic, affective disorder, and normal subjects. Schizophr Res 1996; 20 (1-2): 33-50
16. Clark L, Iversen SD, Goodwin GM. Sustained attention deficit in bipolar disorder. Br J Psychiatry 2002; 180: 313-9
17. McGrath J, Scheldt S, Welham J, et al. Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. Schizophr Res 1997; 26 (2-3): 127-37
18. Zalla T, Joyce C, Szoke A, et al. Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Res 2004; 121 (3): 207-17
19. Thompson JM, Gallagher P, Hughes JH, et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005; 186: 32-40
20. Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull 1995; 117 (2): 285-305
21. Coffman JA, Bornstein RA, Olson SC, et al. Cognitive impairment and cerebral structure by MRI in bipolar disorder. Biol Psychiatry 1990; 27 (11): 1188-96
22. Atre-Vaidya N, Taylor MA, Seidenberg M, et al. Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry Neuropsychol Behav Neurol 1998; 11 (3): 120-6
23. Dixon T, Kravariti E, Frith C, et al. Effect of symptoms on executive function in bipolar illness. Psychol Med 2004; 34 (5): 811-21
24. Larson ER, Shear PK, Krikorian R, et al. Working memory and inhibitory control among manic and euthymic patients with disbipolar disorder. J Int Neuropsychol Soc 2005; 11 (2): 163-72
25. Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006; 93 (1-3): 105-15
26. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr 2006; 28 (3): 252-4
27. Khan A, Ginsberg LD, Asnis GM, et al. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry 2004; 65 (11): 1483-90
28. Daban C, Martinez-Aran A, Torrent C, et al. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J Clin Psychopharmacol 2006; 26 (2): 178-81
29. Jacobsen FM, Comas-Diaz L. Donepezil for psychotropic-induced memory loss. J Clin Psychiatry 1999; 60 (10): 698-704
30. Schrauwen E, Ghaemi SN. Galantamine treatment of cognitive impairment in bipolar disorder: four cases. Bipolar Disord 2006; 8 (2): 196-9
31. Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; 29 (8): 1538-45
32. Baumann B, Bogerts B. Neuroanatomical studies on bipolar disorder. Br J Psychiatry Suppl 2001; 41: S142-7
33. Drevets WC, Ongur D, Price JL. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol Psychiatry 1998; 3 (3): 220-1
34. Lopez-Larson MP, DelBello MP, Zimmerman ME, et al. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry 2002; 52 (2): 93-100
35. Blumberg HP, Stern E, Martinez D, et al. Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry 2000; 48 (11): 1045-52
36. Gruber SA, Rogowska J, Yurgelun-Todd DA. Decreased activation of the anterior cingulate in bipolar patients: an fMRI study. J Affect Disord 2004; 82 (2): 191-201
37. Yurgelun-Todd DA, Gruber SA, Kanayama G, et al. fMRI during affect discrimination in bipolar affective disorder. Bipolar Disord 2000; 2 (3 Pt 2): 237-48
38. Bilder RM, Volavka J, Czobor P, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002; 52 (7): 701-7
39. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98 (12): 6917-22
40. Rosa A, Peralta V, Cuesta MJ, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004; 161 (6): 1110-2
41. Malhotra AK, Kestler LJ, Mazzanti C, et al. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159 (4): 652-4
42. Tsai SJ, Yu YW, Chen TJ, et al. Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci Lett 2003; 338 (2): 123-6
43. Li T, Vallada H, Curtis D, et al. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics 1997; 7 (5): 349-53
44. Mynett-Johnson LA, Murphy VE, Claffey E, et al. Preliminary evidence of an association between bipolar disorder in females and the catechol- O-methyltransferase gene. Psychiatr Genet 1998; 8 (4): 221-5
45. Papolos DF, Veit S, Faedda GL, et al. Ultra-ultra rapid cycling bipolar disorder is associated with the low activity categating cholamine- O-methyltransferase allele. Mol Psychiatry 1998; 3 (4): 346-9
46. Kirov G, Murphy KC, Arranz MJ, et al. Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 1998; 3 (4): 342-5
47. Shifman S, Bronstein M, Sternfeld M, et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128 (1): 61-4
48. Funke B, Malhotra AK, Finn CT, et al. COMT genetic variation confers risk for psychotic and affective disorders: a case conand trol study. Behav Brain Funct 2005; 1: 19-28
49. Burdick KE, Funke B, Goldberg JF, et al. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 2007; 9 (4): 370-6
50. Kimberg DY, D'Esposito M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia 2003; 41 (8): 1020-7
51. Kimberg DY, D'Esposito M, Farah MJ. Effects of bromocrip-tine on human subjects depend on working memory capacity. Neuroreport 1997; 8 (16): 3581-5
52. Luciana M, Collins PF, Depue RA. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb Cortex 1998; 8 (3): 218-26
53. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161 3): 64-6
54. Malhotra AK, Burdick KE, Razi K, et al. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseution dospecificity? Schizophr Res 2006; 87 (1-3): 181-4
55. Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 2003; 169 (3-4): 404-11
56. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159 (6): 1018-28
57. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64 (6): 633-47
58. Shi L, Schuh LM, Trzepacz PT, et al. Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania. Curr Med Res Opin 2004; 20 (9): 1371-6
59. Reinares M, Martinez-Aran A, Colom F, et al. Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients [in Spanish]. Actas Esp Psiquiatr 2000; 28 (4): 231-8
60. Liu L, Wong TP, Pozza MF, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 2004; 304 (5673): 1021-4
61. Cotman CW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988; 11: 61-80
62. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14 (5): 301-7
63. Duncan GE, Moy SS, Perez A, et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 2004; 153 (2): 507-19
64. Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006; 60 (2): 106-14
65. Goldberg TE, Straub RE, Callicott JH, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006; 31 (9): 2022-32
66. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002; 99 (21): 13675-80
67. Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44 (11): 1081-9
68. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57 (6): 577-85
69. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60 (2): 79-88
70. McElroy SL, Zarate CA, Cookson J, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004; 65 (2): 204-10
71. Schmider J, Lammers CH, Gotthardt U, et al. Combined dexamethasone/ corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry 1995; 38 (12): 797-802
72. Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res 1999; 33 (5): 363-70
73. Holsboer F, Lauer CJ, Schreiber W, et al. Altered hypothalamicfor pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995; 62 (4): 340-7
74. Watson S, Gallagher P, Ritchie JC, et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004; 184: 496-502
75. Daban C, Vieta E, Mackin P, et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28 (2): 469-80
76. Watson S, Thompson JM, Ritchie JC, et al. Neuropsychological impairment in bipolar disorder: the relationship with glucocorticoid receptor function. Bipolar Disord 2006; 8 (1): 85-90
77. Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52 (5): 386-92
78. DeBattista C, Belanoff J, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006; 60 (12): 1343-9
79. Simpson GM, El Sheshai A, Loza N, et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 2005; 66 (5): 598-602
80. Velligan DI, Gonzalez JM. Rehabilitation and recovery in schizophrenia. Psychiatr Clin North Am 2007; 30 (3): 535-48
81. Bellack AS. Skills training for people with severe mental illness. Psychiatr Rehabil J 2004; 27 (4): 375-91
82. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the systematic treatment enhancement program. Arch Gen Psychiatry 2007; 64 (4): 419-26
83. Daban C, Martinez-Aran A, Torrent C, et al. Specificity of cognitive deficits in bipolar disorder versus schizophrenia: a systematic review. Psychother Psychosom 2006; 75 (2): 72-84